CLSN - Celsion Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.23
-0.03 (-1.33%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close2.26
Open2.25
Bid0.00 x 0
Ask0.00 x 0
Day's Range2.16 - 2.31
52 Week Range0.22 - 6.06
Volume147,447
Avg. Volume229,761
Market Cap39.56M
Beta1.01
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents28 days ago

    Edited Transcript of CLSN earnings conference call or presentation 27-Mar-18 3:00pm GMT

    Q4 2017 Celsion Corp Earnings Call

  • When Will Celsion Corporation (NASDAQ:CLSN) Become Profitable?
    Simply Wall St.29 days ago

    When Will Celsion Corporation (NASDAQ:CLSN) Become Profitable?

    Celsion Corporation’s (NASDAQ:CLSN): Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer.Read More...

  • Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod
    Zacks4 months ago

    Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod

    Celsion's (CLSN) plan for phase I/II study to evaluate DNA-based immunotherapy, GEN-1, in ovarian cancer gets FDA approval and clearance for initiation.

  • FDA Win Sends Celsion Corporation (CLSN) Shares Higher
    InvestorPlace4 months ago

    FDA Win Sends Celsion Corporation (CLSN) Shares Higher

    The U.S. Food and Drug Administration (FDA) has approved the company’s plans to initiate its OVATION II Study for a DNA-based immunotherapy that’s designed to locally treat ovarian cancer called GEN-1. The company’s Medical Advisory Board helped to develop the Phase I/II trial for Celsion’s drug. The upcoming Phase I/II study from Celsion will begin with a single dose escalation to a higher dose than before in order to help determine what a safe and tolerable dose of the treatment would be, including the study of how an immune system responds to such a dose.

  • Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling
    Zacks4 months ago

    Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling

    Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling

  • Celsion Corporation (CLSN) Shares on the Rise; Here’s Why
    SmarterAnalyst4 months ago

    Celsion Corporation (CLSN) Shares on the Rise; Here’s Why

    Celsion Corporation (NASDAQ:CLSN) investors have a smile on their faces Thursday morning, after the tiny drug maker won FDA clearance for OVATION II Study, the Company’s planned Phase I/II clinical trial of GEN-1, its DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion CEO Michael H. Tardugno added, "GEN-1 holds the potential for tremendous promise as a cancer treatment in the rapidly emerging area of immunotherapy.

  • 5 Breakout Stocks Offering Terrific Returns
    Zacks4 months ago

    5 Breakout Stocks Offering Terrific Returns

    If properly implemented, such a strategy could deliver impressive returns.

  • Capital Cube4 months ago

    ETFs with exposure to Celsion Corp. : January 2, 2018

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Celsion Corp. Here are 5 ETFs with the largest exposure to CLSN-US. Comparing the performance and risk of Celsion Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • SmarterAnalyst5 months ago

    Here’s Why Celsion Corporation Draws a Vote of Confidence from Oppenheimer

    Celsion Corporation (NASDAQ:CLSN) investor sentiment is getting stoked today on back of new bullish attention from Oppenheimer analyst Hartaj Singh. Even though this biotech company has drawn some critical fire circling lead program in ThermoDox in liver cancer, what has Singh making a strong bullish case for "OPTIMA(L) redemption?"

  • Benzinga5 months ago

    7 Stock's Moving In Monday's After-Hours Session

    Gainers: Celsion Corporation (NASDAQ: CLSN ) shares are 18 percent higher after Oppenheimer analyst Hartaj Singh initiated coverage on the company with an Outperform rating and $9 price target. Urban Outfitters, ...

  • Celsion Corporation (CLSN) Shares Climb on Back of New Findings in Liver Tumours Study
    SmarterAnalyst5 months ago

    Celsion Corporation (CLSN) Shares Climb on Back of New Findings in Liver Tumours Study

    Today, shareholders of Celsion Corporation (NASDAQ:CLSN) woke up to a nice 5% pop in the value of their shares, after the drug maker announced publication of the manuscript, "Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours," in the Journal of Therapeutic Ultrasound.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of CLSN earnings conference call or presentation 14-Nov-17 4:00pm GMT

    Q3 2017 Celsion Corp Earnings Call

  • Is It The Right Time To Buy Celsion Corporation (CLSN)?
    Simply Wall St.5 months ago

    Is It The Right Time To Buy Celsion Corporation (CLSN)?

    Celsion Corporation (NASDAQ:CLSN), a biotechnology company based in United States, received a lot of attention from a substantial price increase on the NasdaqCM in the over the last few months.Read More...

  • Celsion Corporation (CLSN) Spooks Investors with a Share Dilution
    SmarterAnalyst6 months ago

    Celsion Corporation (CLSN) Spooks Investors with a Share Dilution

    Shares of Celsion Corporation (NASDAQ:CLSN) dived nearly 20% in morning trade Friday, after the drug maker's stock offering priced at a deep discount. The company said its follow-on offering of 2.64 million shares and warrants priced at $2.50, which is 13% below Thursday's closing price of $2.86. The estimated net proceeds to the Company from the sale of the shares of common stock or warrants in the registered direct offering are expected to be approximately $5.8 million.

  • Cancer Space Last Week Update: Pipeline Expansion in Focus
    Zacks7 months ago

    Cancer Space Last Week Update: Pipeline Expansion in Focus

    Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.

  • Celsion's Immunotherapy Candidate Impresses, Stock Surges
    Zacks7 months ago

    Celsion's Immunotherapy Candidate Impresses, Stock Surges

    Celsion's (CLSN) pipeline candidate, GEN1, controls ovarian cancer in all patients in the phase Ib study and achieves a historical improvement in progression free survival.

  • Capital Cube7 months ago

    ETFs with exposure to Celsion Corp. : September 18, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Celsion Corp. Here are 5 ETFs with the largest exposure to CLSN-US. Comparing the performance and risk of Celsion Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Stocks Near 52-Week Lows: 4 Attractive Picks
    Zacks8 months ago

    Stocks Near 52-Week Lows: 4 Attractive Picks

    Fundamentally strong stocks trading around their 52-week lows make for a great bargain, despite how weak the broader market considers them right now.

  • Celsion Corp. :CLSN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
    Capital Cube8 months ago

    Celsion Corp. :CLSN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Celsion Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Celsion Corp. – ArQule, Inc., ImmunoGen, Inc., Endocyte, Inc., Spectrum Pharmaceuticals, Inc., ZIOPHARM Oncology, Inc., Exelixis, Inc. and Keryx Biopharmaceuticals, Inc. (ARQL-US, IMGN-US, ECYT-US, SPPI-US, ZIOP-US, EXEL-US and KERX-US) ... Read more (Read more...)

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of CLSN earnings conference call or presentation 15-Aug-17 3:00pm GMT

    Q2 2017 Celsion Corp Earnings Call